Default company panoramic image


MitrAssist's minimally invasive valve implant works with the native mitral valve to provide a safe treatment solution for patients with MR.

  • Stage Prototype Ready
  • Industry Medical Devices and Equipment
  • Location Misgav, Karmiel, IL
  • Currency USD
  • Founded October 2009
  • Employees 8
  • Website

Company Summary

Annually, 50,000 patients diagnosed with acute MR cannot undergo open heart surgery, today’s standard treatment option. MitrAssit's solution is suitable for patients unable to undergo surgery, reduces risks and complications,decreases procedure and patient recovery time. MitrAssist estimates the annual potential U.S. market opportunity for newly diagnosed, untreated acute MR patients at $1.5 billion (based on average device costs).


  • Default avatar
    Gil Naor
    Founder and CEO

    18 years’ experience in biomedical engineering; led R&D activity for several medical device companies; inventor of 22 patents; founder of 3 start-ups developing transcatheter valve solutions; recognized as leading Israeli developer of innovative medical devices; B.Sc. mechanical engineering, University of Michigan, M.Sc. biomedical engineering, Stanford University.

  • Default avatar
    Adi Baruch
    VP Business Development

    13 years’ experience in business development and executive management; vast experience in international business development from leading biotech and medical device companies.

  • Default avatar
    Paul Zaletsky

    Over 30 years of R&D and business development in the medical device arena; former VP R&D, Volcano Corporation, with over $1.2 billion market capitalization; former CEO, LumeRx, and co-founder and CTO at Ther.